SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer

Genes and Development

Volumn 30, Issue 19, 2016, Pages 2187-2198

  Tordella, Luca ^a,b   Khan, Sadaf ^a,b   Hohmeyer, Anja ^c   Banito, Ana ^a,b   Klotz, Sabrina ^c   Raguz, Selina ^a,b   Martin, Nadine ^a,b,h   Dhamarlingam, Gopuraja ^a,b   Carroll, Thomas ^a,b   González Meljem, José Mario ^d   Deswal, Sumit ^e   Martínez Barbera, Juan Pedro ^d   García Escudero, Ramón ^f,g   Zuber, Johannes ^e   Zender, Lars ^c   Gil, Jesús ^a,b  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^f CIEMAT   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h CNRS   (France)

Author keywords

ARID1B; Cancer; DNTP metabolism; ENTPD7; P53; Senescence; SWI SNF

Indexed keywords

ENTPD7 ENZYME; ENZYME; PROTEIN P53; PROTEIN SWI; RAS PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG; APYRASE; ARID1B PROTEIN, HUMAN; ARID1B PROTEIN, MOUSE; DNA BINDING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CELL AGING; CONTROLLED STUDY; DNA DAMAGE; ECTOPIC EXPRESSION; EPIGENETICS; GENE CONTROL; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CANCER; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTEIN TARGETING; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CELL LINE; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MUTATION; TUMOR CELL LINE;

ANIMALS; APYRASE; CARCINOMA, HEPATOCELLULAR; CELL AGING; CELL LINE; CELL LINE, TUMOR; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MUTATION; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 84992017361     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.286112.116     Document Type: Article

References (45)

1. Acosta JC, Gil J. 2012. Senescence: a new weapon for cancer therapy. Trends Cell Biol 22: 211–219.
2. Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, et al. 2013. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 15: 978–990.
3. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, et al. 2013. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep 3: 1252– 1265.
4. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, et al. 2009. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev 23: 2134–2139.
5. Barclay RK, Garfinkel E, Phillipps MA. 1962. Effects of 6-diazo-5oxo-L-norleucine on the incorporation of precursors into nucleic acids. Cancer Res 22: 908–914.
6. Barradas M, Anderton E, Acosta JC, Li S, Banito A, RodriguezNiedenfuhr M, Maertens G, Banck M, Zhou MM, Walsh MJ, et al. 2009. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 23: 1177–1182.
7. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih Ie M, Conejo-Garcia JR, et al. 2015. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 21: 231–238.
8. Burrows AE, Smogorzewska A, Elledge SJ. 2010. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci 107: 14280–14285.
9. Chai J, Charboneau AL, Betz BL, Weissman BE. 2005. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res 65: 10192– 10198.
10. Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV. 1999. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet 22: 102–105.
11. Collado M, Serrano M. 2010. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10: 51–57.
12. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. 2009. Protocols to detect senescence-associated β-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4: 1798–1806.
13. Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, Kerkhoven R, Jonkers J, Voorhoeve PM, Agami R, et al. 2010. BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol 12: 380–389.
14. Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak TW, Wang X. 2010. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 143: 711–724.
15. Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai DY, Barbosa IA, Kwon JS, Guan Y, et al. 2013. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 5: 1704–1713.
16. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al. 2012. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44: 760–764.
17. Guan B, Wang TL, Shih Ie M. 2011. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71: 6718–6727.
18. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646–674.
19. Helming KC, Wang X, Roberts CW. 2014a. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 26: 309–317.
20. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, et al. 2014b. ARID1B is a specific vulnerability in ARID1Amutant cancers. Nat Med 20: 251–254.
21. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, et al. 2014. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci 111: 3128–3133.
22. Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ, Koh EY, Daley GQ, et al. 2000. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers. Nat Genet 26: 291–299.
23. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR. 2013. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45: 592–601.
24. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, et al. 2011. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479: 547–551.
25. Khursheed M, Kolla JN, Kotapalli V, Gupta N, Gowrishankar S, Uppin SG, Sastry RA, Koganti S, Sundaram C, Pollack JR, et al. 2013. ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines. Br J Cancer 108: 2056– 2062.
26. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP. 2008. SWI/ SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b–ARF–INK4a locus. Mol Cell Biol 28: 3457–3464.
27. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D. 2005. Glycolytic enzymes can modulate cellular life span. Cancer Res 65: 177–185.
28. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. 2010. The essence of senescence. Genes Dev 24: 2463–2479.
29. Lee D, Kim JW, Seo T, Hwang SG, Choi EJ, Choe J. 2002. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem 277: 22330–22337.
30. Lee JJ, Sholl LM, Lindeman NI, Granter SR, Laga AC, Shivdasani P, Chin G, Luke JJ, Ott PA, Hodi FS, et al. 2015. Targeted nextgeneration sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naive patient melanomas. Clin Epigenetics 7: 59.
31. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. 2011. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 11: 503–511.
32. Narita M, Lowe SW. 2005. Senescence comes of age. Nat Med 11: 920–922.
33. Oruetxebarria I, Venturini F, Kekarainen T, Houweling A, Zuijderduijn LM, Mohd-Sarip A, Vries RG, Hoeben RC, Verrijzer CP. 2004. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem 279: 3807–3816.
34. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. 2013. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 14: 765–780.
35. Robson SC, Sevigny J, Zimmermann H. 2006. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2: 409–430.
36. Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. 2014. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 5: 5295–5303.
37. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA Jr, Papadopoulos N, et al. 2013. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 45: 12–17.
38. Shain AH, Pollack JR. 2013. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One 8: e55119.
39. Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih Ie M, et al. 2015. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov 5: 752–767.
40. Shi JD, Kukar T, Wang CY, Li QZ, Cruz PE, Davoodi-Semiromi A, Yang P, Gu Y, Lian W, Wu DH, et al. 2001. Molecular cloning and characterization of a novel mammalian endo-apyrase (LALP1). J Biol Chem 276: 17474–17478.
41. Trouche D, Le Chalony C, Muchardt C, Yaniv M, Kouzarides T. 1997. RB and hbrm cooperate to repress the activation functions of E2F1. Proc Natl Acad Sci 94: 11268–11273.
42. ′ -diphosphate. Biochemistry 48: 11612–11621.
43. Watson IR, Takahashi K, Futreal PA, Chin L. 2013. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 14: 703–718.
44. Wilson BG, Roberts CW. 2011. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11: 481–492.
45. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, et al. 2008. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135: 852–864.